Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases
Authors' conclusion
In a large, real-world cohort, 29.8% of persons with systemic autoimmune disease reported PASC, often affecting QOL.
Study context
- Population
- Adults aged ≥ 18 years with systemic autoimmune diseases reporting SARS-CoV-2 infection, national prospective cohort recruited December 2020–April 2021299 PASC survey respondents
- Participants
- 1,615 adults
- Exposure
- Participants who did vs did not report PASC
- PASCn = 89
- Outcome
- PASC (≥ 1 symptom persisting for > 12 weeks)
- Follow-up
- > 12 weeks
Methodological detailsnational, observational
- National
- Observational
Main finding
As reported in the abstract
PASC prevalence among respondents
PASC
29.8%
89
Observational data: associations, not effects.
Further findings
Reinfections
P = 0.004
Median
| Outcome | PASC | No PASC | P value |
|---|---|---|---|
| Number of preceding vaccines | 2 (IQR 2–3) | 3 (IQR 2–3) | P < 0.001 |
- Most reported symptom domain in PASC: neurological/psychological
- 83.1%
- Effect on quality of life (QOL) in PASC
- 84%
Original publication
Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases. J Rheumatol. Published 1 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →